Search

Your search keyword '"Daina, E."' showing total 91 results

Search Constraints

Start Over You searched for: Author "Daina, E." Remove constraint Author: "Daina, E."
91 results on '"Daina, E."'

Search Results

1. C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial

7. C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial

9. Cluster analysis identifies distinct pathogenetic patterns in c3 glomerulopathies/immune complex–Mediated membranoproliferative GN

10. Liver-kidney transplantation to cure atypical hemolytic uremic syndrome

11. Left main stem patch plasty and aortic root homograft in Takayasu's disease

12. The Italian National Rare Diseases Registry

13. I can do text analytics!

17. Recurrence of hemolytic uremic syndrome/thrombotic thrombocytopenic purpura after transplantation: outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background

18. Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies

19. Liver-kidney transplantation to cure atypical hemolytic uremic syndrome

20. Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: A case report

23. Mycophenolate mofetil for the treatment of Takayasu arteritis: report of three cases.

24. Rare Kidney Diseases

29. Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex–Mediated Membranoproliferative GN

30. Left main stem patch plasty and aortic root homograft in Takayasu's disease

31. Monogenic diseases that can be cured by liver transplantation

32. Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies

33. Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: A case report

34. Efficacy and Safety of Pegcetacoplan in Kidney Transplant Recipients With Recurrent Complement 3 Glomerulopathy or Primary Immune Complex Membranoproliferative Glomerulonephritis.

35. Lysinuric Protein Intolerance: Not Only a Disorder for Pediatric Nephrologists - Case Report.

37. Functional Magnetic Resonance Imaging to Monitor Disease Progression: A Prospective Study in Patients with Primary Membranoproliferative Glomerulonephritis.

38. Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.

39. A GWAS in the pandemic epicenter highlights the severe COVID-19 risk locus introgressed by Neanderthals.

40. Membranoproliferative glomerulonephritis: no longer the same disease and may need very different treatment.

41. Kidney diseases.

42. Clinical Outcomes of Patients with C3G or IC-MPGN Treated with the Factor D Inhibitor Danicopan: Final Results from Two Phase 2 Studies.

43. Baseline Clinical Characteristics and Complement Biomarkers of Patients with C3 Glomerulopathy Enrolled in Two Phase 2 Studies Investigating the Factor D Inhibitor Danicopan.

44. Improving diagnosis for rare diseases: the experience of the Italian undiagnosed Rare diseases network.

45. Morphofunctional Effects of C5 Convertase Blockade in Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Report of Two Cases with Evidence of Terminal Complement Activation.

46. Urinary proteome signature of Renal Cysts and Diabetes syndrome in children.

47. Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN.

48. Rare Diseases in Europe: from a Wide to a Local Perspective.

49. Liver transplantation for aHUS: still needed in the eculizumab era?

50. Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome.

Catalog

Books, media, physical & digital resources